Skip to main content

Table 1 Clinical and demographic characteristics of the mECT and aECT groups

From: Clinical characteristics and potential association to Parkinson’s disease and dementia with Lewy bodies in patients with major depressive disorder who received maintenance electroconvulsive therapy: a retrospective chart review study

 

mECT (n = 13)

aECT

mECT vs

all aECT

p-value

mECT vs. over 1-year aECT

p-value

 

All

(n = 146)

Followed up over 1 year (n = 73)

Male sex

3 (23.1)

64 (43.8)

26 (35.6)

0.146

0.529

Age at the first ECT (years)

76.7 [7.4]

62.0 [14.6]

63.5 [13.6]

 < 0.001

0.002

Age at MDD onset (years)

64.0[9.1]

55.3 [7.2]

56.5 [16.0]

0.007

0.009

Number of ECT sessions

9.15 [1.62]

8.99 [2.64]

9.32 [2.50]

0.829

0.824

Number of previous depressive episodes

3.5 [1.9]

2.3 [1.8]

2.4 [1.8]

0.016

0.039

Duration of MDD (months)

75.3 [56.7]

76.4 [88.2]

80.8 [96.9]

0.966

0.239

Duration of the current depressive episode (months)

10.1 [9.5]

18.8 [38.2]

18.0 [41.4]

0.414

0.495

Number of suicide attempts

2 (15.4)

20 (13.7)

9 (12.3)

0.564

0.670

Family history of MDD

1 (7.7)

28 (19.2)

16 (21.9)

0.465

0.449

Melancholic features

12 (92.3)

40 (27.4)

15 (20.5)

 < 0.001

 < 0.001

Psychotic features

3 (23.1)

48 (32.9)

24 (32.9)

0.350

0.747

Catatonic features

6 (46.2)

14 (9.6)

5 (6.8)

0.002

 < 0.001

Baseline CGI-S

5.4 [1.3]

4.8 [1.4]

4.8 [1.4]

0.140

0.187

Post-treatment c-CGI

1.4 [0.7]

1.6 [0.9]

1.4 [0.7]

0.475

0.815

DDD at pre-ECT

 Antidepressants

0.96 [0.89]

1.24 [0.95]

1.22 [1.01]

0.298

0.381

 Antipsychotics

0.19[0.26]

0.29 [0.58]

0.28 [0.49]

0.525

0.492

 Anti-anxiety drugs

0.15 [0.21]

0.14 [0.35]

0.18 [0.44]

0.892

0.818

 Hypnotics

0.31 [0.43]

0.74 [0.95]

0.71 [0.76]

0.106

0.065

 Anti-epileptic drugs

0

18.8 [38.2]

0

0.498

n/a

 Mood stabilizers

0

0.02 [0.20]

0

0.764

n/a

 Antidementia drugs

0

0.01 [0.06]

0.01 [0.09]

0.683

0.564

Number of prescriptions at pre-ECT

 Antidepressants

9 (69.2)

122 (83.6)

62 (84.9)

0.226

0.215

 Antipsychotics

7 (53.8)

71 (48.6)

35 (47.9)

0.772

0.728

 Anti-anxiety drugs

5 (38.4)

27 (18.5)

14 (19.2)

0.143

0.154

 Hypnotics

5 (38.4)

81 (55.5)

45 (61.6)

0.207

0.105

 Anti-epileptic drugs

0

6 (4.1)

0

0.451

0.762

 Mood stabilizers

0

1 (0.7)

0

0.762

n/a

 Antidementia drugs

0

2 (1.4)

2 (2.7)

0.671

0.546

 MMSE at pre-ECT a

24.67 [4.51]

27.39 [2.81]

27.21 [3.15]

0.112

0.202

 MMSE at post-ECT b

24.00 [2.65]

27.11 [3.10]

27.00 [3.49]

0.097

0.168

  1. Data are present as the mean [SD] or n (%)
  2. amECT, all aECT, and 1 year followed up aECT included 3, 66, and 33 patients, respectively
  3. bmECT, all aECT, and 1 year followed up aECT included 3, 46, and 22 patients, respectively
  4. aECT Acute electroconvulsive therapy, cCGI Clinical Global Impression Improvement scale, CGI-S Clinical Global Impression–Severity Scale, DDD Defined Daily Dose, mECT Maintenance electroconvulsive therapy, MDD Major depressive disorder, MMSE Mini Mental State Examination
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us